These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel. Page AT; Potter K; Clifford R; McLachlan AJ; Etherton-Beer C Intern Med J; 2016 Oct; 46(10):1189-1197. PubMed ID: 27527376 [TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management. Widschwendter CG; Hofer A Curr Opin Psychiatry; 2019 May; 32(3):179-184. PubMed ID: 30720484 [TBL] [Abstract][Full Text] [Related]
14. Deutetrabenazine in the treatment of tardive dyskinesia. Niemann N; Jimenez-Shahed J Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019 [TBL] [Abstract][Full Text] [Related]
16. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment. Citrome L; Saklad SR J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259 [TBL] [Abstract][Full Text] [Related]
17. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Sarva H; Henchcliffe C Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466 [TBL] [Abstract][Full Text] [Related]
18. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia. Jackson R; Brams MN; Carlozzi NE; Citrome L; Fritz NE; Hoberg AR; Isaacson SH; Kane JM; Kumar R J Clin Psychiatry; 2022 Nov; 84(1):. PubMed ID: 36449471 [No Abstract] [Full Text] [Related]